Europäisches Patentamt
European Patent Office
Office européen des brevets

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 20 80 48 11

Classification of the application (IPC):
A61P 5/48*, *A61K 38/28*, *A61P 5/50

Technical fields searched (IPC):
C07K

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
X Y	**Anonymous**: "Anti-CD3 Prevention ANTI-CD3 MAB (TEPLIZUMAB) FOR PREVENTION OF DIABETES IN RELATIVES AT-RISK FOR TYPE 1 DIABETES MELLITUS (Protocol TN-10)" *Type 1 Diabetes TrialNet*, 25 June 2014 (2014-06-25) URL: https://clinicaltrials.gov/ProvidedDocs/61/NCT01030861/Prot_000.pdf [retrieved on 09 February 2022 (2022-02-09)] XP055889308 * the whole document * * in particular, pages 13-14 *	1, 2, 4-7, 9-13 3-13
Y	**LONG ET AL.**: "Partial exhaustion of CD 8 T cells and clinical response to teplizumab in new-onset type 1 diabetes" *SCIENCE IMMUNOLOGY*, 18 November 2016 (2016-11-18), vol. 1, no. 5, XP055760444 * the whole document * * in particular, abstract and pages 7-8 *	3-13
Y	WO 2015073833 A1 (PHARMACYCLICS INC [US]; KENDALL PEGGY L [US]) 21 May 2015 (2015-05-21) * the whole document * * in particular, paragraph 2 *	2-13
Y	WO 2007147090 A2 (MACROGENICS INC [US]; KOENIG SCOTT [US] ET AL.) 21 December 2007 (2007-12-21) * the whole document * * in particular, example 6.2, pages 139-140 *	2-13
A	**MANNERING S I ET AL**: "The case for an autoimmune aetiology of type 1 diabetes" *CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB*, 21 October 2015 (2015-10-21), vol. 183, no. 1, DOI: 10.1111/CEI.12699, ISSN: 0009-9104, pages 8-15, XP071082897 * the whole document *	1-13

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search	Date of completion of the search	Examiner
Munich	09 February 2022	Pérez-Mato, Isabel

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A: technological background
O: non-written disclosure
P: intermediate document
T: theory or principle underlying the invention
E: earlier patent document, but published on, or after the filing date
D: document cited in the application
L: document cited for other reasons
& : member of the same patent family, corresponding document

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.

EP 3 873 601 A4

© 2020 org.epo.publication.kb xsl stylesheet v1.0.1SRnfp

Europäisches Patentamt
European Patent Office
Office européen des brevets

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 20 80 48 11

DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
A	**WHERRETT DIANE K. ET AL**: "Prevention of Type 1 Diabetes" *ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA.* PHILADELPHIA 01 December 2009 (2009-12-01), vol. 38, no. 4, DOI: 10.1016/j.ecl.2009.08.006, ISSN: 0889-8529, pages 777-790, XP055889301 * the whole document * * in particular, pages 5-6 *	1, 2, 4-7, 9-13
A	**WU YAN-LING ET AL**: "Risk Factors and Primary Prevention Trials for Type 1 Diabetes" *INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES*, 18 July 2013 (2013-07-18), vol. 9, no. 7, DOI: 10.7150/ijbs.6610, ISSN: 1449-2288, pages 666-679, XP055889302 * the whole document * * in particular, pages 673-674 *	1, 2, 4-7, 9-13
A	**JANELLE A NOBLE ET AL**: "Genetics of the HLA Region in the Prediction of Type 1 Diabetes" *CURRENT DIABETES REPORTS, CURRENT SCIENCE INC, NEW YORK*, 13 September 2011 (2011-09-13), vol. 11, no. 6, DOI: 10.1007/S11892-011-0223-X, ISSN: 1539-0829, pages 533-542, XP019971883 * the whole document * * in particular, pages 537-538 *	10
X,P	**KEVAN C. HEROLD ET AL**: "An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes" *THE NEW ENGLAND JOURNAL OF MEDICINE* US 15 August 2019 (2019-08-15), vol. 381, no. 7, DOI: 10.1056/NEJMoa1902226, ISSN: 0028-4793, pages 603-613, XP055760445 * the whole document *	1-13

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

Place of search	Date of completion of the search	Examiner
Munich	09 February 2022	Pérez-Mato, Isabel

CATEGORY OF CITED DOCUMENTS

X: particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A: technological background
O: non-written disclosure
P: intermediate document
T: theory or principle underlying the invention
E: earlier patent document, but published on, or after the filing date
D: document cited in the application
L: document cited for other reasons
& : member of the same patent family, corresponding document

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.

EP 3 873 601 A4

© 2020 org.epo.publication.kb xsl stylesheet v1.0.1SRnfp

Europäisches Patentamt
European Patent Office
Office européen des brevets

ANNEX TO SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application number:
EP 20 80 48 11

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on 09-02-2022
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 2015073833	A1	21-05-2015	US	2015141438 A1	21-05-2015
			WO	2015073833 A1	21-05-2015
WO 2007147090	A2	21-12-2007	AU	2007260687 A1	21-12-2007
			BR	PI0713426 A2	09-10-2012
			CA	2655080 A1	21-12-2007
			EP	2037961 A2	25-03-2009
			EP	2815764 A1	24-12-2014
			HK	1204994 A1	11-12-2015
			JP	2009544761 A	17-12-2009
			SG	177907 A1	28-02-2012
			SG	10201504662W A	30-07-2015
			US	2008095766 A1	24-04-2008
			US	2016046714 A1	18-02-2016
			WO	2007147090 A2	21-12-2007

EP 3 873 601 A4

© 2020 org.epo.publication.kb xsl stylesheet v1.0.1SRnfp

Disclaimer: this document has been automatically generated using data structured in accordance with WIPO standard ST.36 from the database of search reports of the European Patent Office. For technical reasons, its content and layout may differ from that of the original publication. Only the original published information is legally binding.